Investors

Agios Pharmaceuticals has received European Commission approval for PYRUKYND® (mitapivat) in adults with thalassaemia. Avanzanite will commercialise and distribute the therapy across Europe under its exclusive partnership with Agios.

Avanzanite expands into France and welcomes Constance Sabbagh as General Manager — bringing over two decades of rare disease expertise to one of Europe's most important healthcare markets.

Avanzanite Bioscience has secured €32M in Series A funding from MVM Partners to expand its reach and improve access to rare disease medicines across Europe.

A positive CHMP opinion for PYRUKYND® marks an important step towards improving access to treatment for adults with thalassemia across Europe.

Avanzanite Bioscience has partnered with Agios to bring PYRUKYND® to patients across Europe, improving access to treatment for rare blood disorders.

Avanzanite Bioscience has partnered with Advicenne to bring Sibnayal® to patients across Europe, improving access to treatment for rare kidney disease.

Avanzanite Bioscience has launched a new model to improve access to rare disease medicines across Europe, helping more patients receive the treatments they need.